Comparative study of the efficacy and safety of ceftazidime/avibactam plus metronidazole versus meropenem in the treatment of complicated intra-abdominal infections in hospitalized adults: Results of a randomized, double-blind, phase II trial

Journal of Antimicrobial Chemotherapy

Volumn 68, Issue 5, 2013, Pages 1183-1192

  Lucasti, Christopher ^a   Popescu, Irinel ^b   Ramesh, Mayakonda K ^c   Lipka, Joy ^d,e   Sable, Carole ^d,f  

^a South Jersey Infectious Disease   (United States)

^b FUNDENI CLINICAL INSTITUTE   (Romania)

^c Bangalore Medical College and Research Institute ^*  (India)

^d ASTRAZENECA   (United Kingdom)

^e Cerexa Inc   (United States)

^f MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Appendix; Ceftazidime non susceptible; Escherichia coli; Stomach duodenum

Indexed keywords

AVIBACTAM; CEFTAZIDIME; MEROPENEM; METRONIDAZOLE; PLACEBO;

ABDOMINAL INFECTION; ADULT; AGED; ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; FEMALE; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; PHASE 2 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT DURATION; TREATMENT RESPONSE;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; AZABICYCLO COMPOUNDS; CEFTAZIDIME; DOUBLE-BLIND METHOD; DRUG TOXICITY; FEMALE; HUMANS; INTRAABDOMINAL INFECTIONS; MALE; METRONIDAZOLE; MIDDLE AGED; PLACEBOS; THIENAMYCINS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84877123198     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dks523     Document Type: Article

References (23)

1. Solomkin JS, Mazuski JE, Bradley JS et al. Diagnosis and management of complicated intra-abdominal infection in adults and children: guidelines by the Surgical Infection Society and the Infectious Diseases Society of America. Clin Infect Dis 2010; 50: 133-64.
2. Hoban DJ, Bouchillon SK, Hawser SP et al. Susceptibility of Gram-negative pathogens isolated from patients with complicated intra-abdominal infections in the United States, 2007-2008: results of the Study for Monitoring Antimicrobial Resistance Trends (SMART). Antimicrob Agents Chemother 2010; 54: 3031-4.
3. Kanj SS, Kanafani ZA. Current concepts in antimicrobial therapy against resistant Gram-negative organisms: extended-spectrum β-lactamaseproducing Enterobacteriaceae, carbapenem-resistant Enterobacteriaceae, and multidrug-resistant Pseudomonas aeruginosa. Mayo Clin Proc 2011; 86: 250-9.
4. Bratu S, Landman D, Haag R et al. A rapid spread of carbapenem resistant Klebsiella pneumoniae in New York City: a new threat to our antibiotics armamentarium. Arch Intern Med 2005; 165: 1430-5.
5. Nordmann P, Cuzon G, Naas T. The real threat of Klebsiella pneumoniae carbapenemase-producing bacteria. Lancet Infect Dis 2009; 9: 228-36.
6. Hawser SP, Bouchillon SK, Lascols C et al. Susceptibility of Klebsiella pneumoniae isolates from intra-abdominal infections and molecular characterization of ertapenem-resistant isolates. Antimicrob Agents Chemother 2011; 55: 3917-21.
7. Stachyra T, Levasseur P, Péchereau MC et al. In vitro activity of the β-lactamase inhibitor NXL104 against KPC-2 carbapenemase and Enterobacteriaceae expressing KPC carbapenemases. J Antimicrob Chemother 2009; 64: 326-9.
8. Livermore DM, Mushtaq S, Warner M et al. NXL104 combinations versus Enterobacteriaceae with CTX-M extended-spectrum β-lactamases and carbapenemases. J Antimicrob Chemother 2008; 62: 1053-6.
9. Walkty A, DeCorby M, Lagacé-Wiens PR et al. In vitro activity of ceftazidime combined with NXL104 versus Pseudomonas aeruginosa isolates obtained from patients in Canadian hospitals (CANWARD 2009 study). Antimicrob Agents Chemother 2011; 55: 2992-4.
10. Levasseur P, Girard AM, Delachaume C et al. NXL104, a novel β-lactamase inhibitor, restores the bactericidal activity of ceftazidime against ESBL and AmpC producing strains of Enterobacteriaceae. In: Abstracts of the Forty-sixth Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, CA, 2006. Abstract F127. American Society for Microbiology, Washington, DC, USA. http://ebookbrowse.com/2006-icaac-nxl-104-levasseur-poster-f-127-pdf-d76709134 (2 November 2011, date last accessed).
11. Levasseur P, Girard AM, Lavallade L et al. Use of the hollow fibre infection model in the pharmacodynamic evaluation of the β-lactamase inhibitor NXL104. Clin Microbiol Infect 2009; 15 Suppl S4: S410 (Abstract P1463).
12. Endimiani A, Choudhary Y, Bonomo RA. In vitro activity of NXL104 in combination with b-lactams against Klebsiella pneumoniae isolates producing KPC carbapenemases. Antimicrob Agents Chemother 2009; 53: 3599-601.
13. Endimiani A, Hujer KM, Hujer AM et al. Evaluation of ceftazidime and NXL104 in two murine models of infection due to KPC-producing Klebsiella pneumoniae. Antimicrob Agents Chemother 2011; 55: 82-5.
14. Clinical and Laboratory Standards Institute. Performance Standards for Antimicrobial Susceptibility Testing: Twentieth Informational Supplement M100-S20. Wayne, PA, USA, 2010.
15. Flagyl (Metronidazole) Solution for Infusion: Summary of Product Characteristics. Winthrop Pharmaceuticals UK Ltd, May 2011. http://www.medicines.org.uk/EMC/medicine/26714/SPC/Flagyl+Injection/ (9 January 2013, date last accessed).
16. Weigelt JA. Empiric treatment options in the management of complicated intra-abdominal infections. Cleveland Clinic J Med 2007; 74 Suppl 4: S29-37.
17. Hawser SP, Bouchillon SK, Hoban DJ, Badal RE. Epidemiologic trends, occurrence of extended-spectrum β-lactamase production, and performance of ertapenem and comparators in patients with intra-abdominal infections: analysis of global trend data from 2002-2007 from the SMART study. Surg Infect (Larchmt) 2010; 11: 371-8.
18. Hawser SP, Bouchillon SK, Hoban DJ et al. Incidence and antimicrobial susceptibility of Escherichia coli and Klebsiella pneumoniae with extended-spectrum β-lactamases in community- and hospitalassociated intra-abdominal infections in Europe: results of the 2008 Study for Monitoring Antimicrobial Resistance Trends (SMART). Antimicrob Agents Chemother 2010; 54: 3043-6.
19. Hawser SP, Badal RE, Bouchillon SK et al. Antibiotic susceptibility of intra-abdominal infection isolates from Indian hospitals during 2008. J Med Microbiol 2010; 59: 1050-4.
20. Hsueh PR, Badal RE, Hawser SP et al. Epidemiology and antimicrobial susceptibility profiles of aerobic and facultative Gram-negative bacilli isolated from patients with intra-abdominal infections in the Asia-Pacific region: 2008 results from SMART (Study for Monitoring Antimicrobial Resistance Trends). Int J Antimicrob Agents 2010; 36: 408-14.
21. Lucasti C, Jasovich A, Umeh O et al. Efficacy and tolerability of iv doripenem versus meropenem in adults with complicated intra-abdominal infection: a phase III, prospective, multicenter, randomized, double-blind, noninferiority study. Clin Ther 2008; 30: 868-83.
22. Lagacé-Wiens PR, Tailor F, Simner P et al. Activity of NXL104 in combination with b-lactams against genetically characterized Escherichia coli and Klebsiella pneumoniae isolates producing class A extended-spectrum β-lactamases and class C β-lactamases. Antimicrob Agents Chemother 2011; 55: 2434-7.
23. Livermore DM, Mushtaq S, Warner M et al. Activities of NXL104 combinations with ceftazidime and aztreonam against carbapenemaseproducing Enterobacteriaceae. Antimicrob Agents Chemother 2011; 55: 390-4.